Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Olaparib may delay metastatic pancreatic cancer in patients
Cancer Trial Results
Efficacy – LYNPARZA® (olaparib)
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
Cureus | Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
Treatment Paradigm – LYNPARZA® (olaparib)
POLO Trial Shows Maintenance Olaparib Improves PFS in Metastatic Pancreatic Cancer - The ASCO Post
Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter
Asco 2019 – Polo reveals an overall survival hole | Evaluate
ASCO GI 2021: Results From the Phase 3 POLO Trial
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
ASCO GI 2021: Results From the Phase 3 POLO Trial
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Treatment landscape of metastatic pancreatic cancer - Cancer Treatment Reviews
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
Efficacy – LYNPARZA® (olaparib)
Efficacy – LYNPARZA® (olaparib)
ASCO GI 2021: Results From the Phase 3 POLO Trial
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
5697_O REILLY Transcript.indd
